Cipla Ltd.

Cipla’s wholly owned subsidiary -- Cipla EU has entered into a joint venture agreement with Jiangsu Acebright Pharmaceutical Company (Acebright), China on July 15, 2019 for incorporation of a joint venture (JV) company in China.

The JV Company will be in the business of manufacturing, selling and distribution of pharmaceutical products, research and development services, analytical development services with the purpose of providing high quality and affordable drugs.

As per the agreement, Cipla EU will hold 80% stake and Acebright will hold 20% stake in the JV Company. Cipla EU's investment in the JV Company is estimated up to $24 million over a period of 4 years.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.